Z
Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
Price:
25.31
CNY
-0.47%
Market Closed
Market Cap:
¥8.8B
Relative Value
The Relative Value of one Zhejiang Tianyu Pharmaceutical Co Ltd stock under the Base Case scenario is 31.18 CNY. Compared to the current market price of 25.31 CNY, Zhejiang Tianyu Pharmaceutical Co Ltd is Undervalued by 19%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
31.18
CNY
Undervaluation 19%
Z
Multiples Across Competitors
Competitors Multiples
Zhejiang Tianyu Pharmaceutical Co Ltd Competitors
Zhejiang Tianyu Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
Z
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
|
8.8B CNY | 2.9 | 45.9 | 43.2 | 43.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987B USD | 15.1 | 47.8 | 32.2 | 34.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.7B USD | 6.3 | 22.1 | 15.3 | 18.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
298.4B CHF | 4.9 | 31.7 | 13.3 | 15.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.8B GBP | 5.5 | 31.8 | 17.5 | 24.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
248.3B CHF | 5.7 | 22.8 | 14 | 18.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
309B USD | 4.8 | 16.9 | 10.6 | 12.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.7 | 7.9 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD | 2.5 | 19.9 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.1B USD | 2.6 | 17.6 | 7.4 | 9.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
